MX2016013245A - Regimen de dosificacion de liberacion inmediata de moduladores s1p. - Google Patents

Regimen de dosificacion de liberacion inmediata de moduladores s1p.

Info

Publication number
MX2016013245A
MX2016013245A MX2016013245A MX2016013245A MX2016013245A MX 2016013245 A MX2016013245 A MX 2016013245A MX 2016013245 A MX2016013245 A MX 2016013245A MX 2016013245 A MX2016013245 A MX 2016013245A MX 2016013245 A MX2016013245 A MX 2016013245A
Authority
MX
Mexico
Prior art keywords
immediate release
release dosage
modulator
dosage regimen
siponimod
Prior art date
Application number
MX2016013245A
Other languages
English (en)
Spanish (es)
Inventor
Wallstroem Erik
Legangneux Eric
Michel Rene Bouillot Philippe
Reynaud Emeric
Dehlke Frank
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52988364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016013245(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2016013245A publication Critical patent/MX2016013245A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2016013245A 2014-04-10 2015-04-08 Regimen de dosificacion de liberacion inmediata de moduladores s1p. MX2016013245A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461977816P 2014-04-10 2014-04-10
PCT/IB2015/052550 WO2015155709A1 (en) 2014-04-10 2015-04-08 S1p modulator immediate release dosage regimen

Publications (1)

Publication Number Publication Date
MX2016013245A true MX2016013245A (es) 2017-01-16

Family

ID=52988364

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013245A MX2016013245A (es) 2014-04-10 2015-04-08 Regimen de dosificacion de liberacion inmediata de moduladores s1p.

Country Status (16)

Country Link
US (4) US20170027907A1 (enExample)
EP (3) EP3831378A1 (enExample)
JP (1) JP6674903B2 (enExample)
KR (2) KR20220156981A (enExample)
CN (2) CN106456552A (enExample)
AU (2) AU2015246036A1 (enExample)
CA (1) CA2943598C (enExample)
CL (1) CL2016002562A1 (enExample)
IL (2) IL305337A (enExample)
MX (1) MX2016013245A (enExample)
PH (1) PH12016501965A1 (enExample)
RU (2) RU2715734C2 (enExample)
SG (1) SG11201607894RA (enExample)
TW (1) TW201622721A (enExample)
WO (1) WO2015155709A1 (enExample)
ZA (1) ZA201606519B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (enExample) 2014-01-24 2018-02-24
EP3831378A1 (en) * 2014-04-10 2021-06-09 Novartis AG Siponimod immediate release dosage regimen for treating autoimmune diseases
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
CA3074416A1 (en) * 2017-09-29 2019-04-04 Novartis Ag Dosing regimen of siponimod
MX2020007268A (es) * 2017-09-29 2020-08-17 Novartis Ag Regimen de dosificacion de siponimod.
FI3758708T3 (fi) * 2018-03-01 2025-02-18 Astrazeneca Ab (2s)-{(1s)-1-syano-2-[4-(3-metyyli-2-okso-2,3-dihydro-1,3-bentsoksatsol-5-yyli)fenyyli]etyyli}-1,4-oksatsepaani-2-karboksamidia käsittäviä farmaseuttisia koostumuksia
KR20210032431A (ko) 2018-07-17 2021-03-24 인스메드 인코포레이티드 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
CN109908095A (zh) * 2019-04-08 2019-06-21 肇庆学院 一种西尼莫德片剂及制备方法
TW202131921A (zh) 2019-10-31 2021-09-01 瑞士商愛杜西亞製藥有限公司 Cxcr7拮抗劑與s1p1受體調節劑之組合
WO2021158838A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor modulator
EP4646265A1 (en) 2023-01-06 2025-11-12 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53041B (sr) * 2008-12-18 2014-04-30 Novartis Ag Hemifumaratna so 1-[4-[1-(4-cikloheksil-3-trifluorometil-benziloksiimino)-etil]-2-etil-benzil]-azetidin-3-karboksilne kiseline
WO2010072703A1 (en) * 2008-12-22 2010-07-01 Novartis Ag Dosage regimen of an s1p receptor agonist
PL2379067T3 (pl) * 2008-12-22 2016-02-29 Novartis Ag Schemat dawkowania fingolimodu w leczeniu stwardnienia rozsianego
EP3061449A1 (en) * 2009-09-29 2016-08-31 Novartis AG Dosage regimen of an s1p receptor modulator
JP6111202B2 (ja) * 2011-01-07 2017-04-05 ノバルティス アーゲー 免疫抑制製剤
WO2012095853A1 (en) * 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
US20150218090A1 (en) * 2011-10-21 2015-08-06 Novartis Ag Dosage regimen for an s1p receptor modulator or agonist
EP3831378A1 (en) * 2014-04-10 2021-06-09 Novartis AG Siponimod immediate release dosage regimen for treating autoimmune diseases

Also Published As

Publication number Publication date
AU2015246036A1 (en) 2016-10-13
EP4074312C0 (en) 2026-02-25
US20220016076A1 (en) 2022-01-20
CN106456552A (zh) 2017-02-22
IL247986A0 (en) 2016-11-30
EP4074312A1 (en) 2022-10-19
PH12016501965A1 (en) 2017-01-09
AU2020203107B2 (en) 2021-10-21
US20250041266A1 (en) 2025-02-06
RU2715734C2 (ru) 2020-03-03
CA2943598C (en) 2023-03-07
RU2020107732A (ru) 2020-03-30
RU2016143979A3 (enExample) 2018-11-12
US20190054065A1 (en) 2019-02-21
EP4074312B1 (en) 2026-02-25
WO2015155709A1 (en) 2015-10-15
TW201622721A (zh) 2016-07-01
EP3129020A1 (en) 2017-02-15
JP6674903B2 (ja) 2020-04-01
CN116650467A (zh) 2023-08-29
CA2943598A1 (en) 2015-10-15
AU2020203107A1 (en) 2020-05-28
KR20160141841A (ko) 2016-12-09
JP2017510607A (ja) 2017-04-13
IL305337A (en) 2023-10-01
KR20220156981A (ko) 2022-11-28
EP3831378A1 (en) 2021-06-09
US20170027907A1 (en) 2017-02-02
ZA201606519B (en) 2017-11-29
SG11201607894RA (en) 2016-10-28
CL2016002562A1 (es) 2017-07-28
RU2016143979A (ru) 2018-05-14

Similar Documents

Publication Publication Date Title
DOP2016000291A (es) Composiciones y métodos para modular la expresión del factor b del complemento
PH12016501965A1 (en) S1p modulator immediate release dosage regimen
MX2017005106A (es) Metodos y composiciones para dosificacion en terapia celular adoptiva.
GT201500312A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b
MX2016000271A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
BR112016014410A2 (pt) terapia de combinação com vacina de neoantígeno
NI201500140A (es) Compuestos y composiciones terapéuticos
SV2017005489A (es) Terapias de combinación para el tratamiento de cánceres
MX392839B (es) Liberacion autorregulada de ingrediente farmaceutico activo.
MX2014015005A (es) Formas cristalinas de un modulador del receptor androgenico.
MX356052B (es) Terapias sinergicas de cannabidiol con hipotermia para neuroproteccion.
CL2015001610A1 (es) Compuestos derivados de pirimido-[4,5-b]-quinolina-4,5(3h,10h)-dionas para utilizarse como un medicamento para el tratamiento de una enfermedad causada por una mutacion sin sentido; composicion y combinacion farmaceutica que los comprende.
NI201400112A (es) Tratamiento del cáncer con inhibidores tor cinasa
ECSP16012582A (es) Compuestos heterocíclicos y métodos de uso
MX2020004516A (es) Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas.
CL2020000812A1 (es) Semaglutida en la terapia médica.
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
GT201500035A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
AR099558A1 (es) Régimen de dosaje del compuesto fgf-18
MX2015012444A (es) Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos.
BR112015025719A2 (pt) terapia contra o câncer
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
BR112015029894A2 (pt) forma de dosagem farmacêutica sólida
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
EA201691860A1 (ru) Пептидный медикамент в виде сухого порошка